Back
Return
Biography

Dr. Upal Roy

Florida International University, USA

Email: uroy@fiu.edu

Qualifications

2005  Ph.D., Goa University, India

1999  M.S., Marathwada University, India

1997  B.S., Marathwada University, India

Publications (selected)


  1. Upal Roy, C Bulot, K H Z Bentrupand DMondal.2013. Specific Increase in MDR1 Mediated Drug-Efflux in Human Brain Endothelial Cells Following Co-exposure to HIV-1 and Saquinavir. PLoS One. 2013 Oct 3;8(10):e75374.
  2. SL Gerlach, M Yeshak, U Göransson,  Upal Roy, R Izadpanah, D Mondal. 2013. Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells.Biopolymers. 2013;100(5):471-479.(PMID:23897405)
  3. N Gautam, UpalRoy , S Balkundi, P Puligujja, D Guo, N Smith, XM Liu, B Lamberty, B Morsey, H Fox, J McMillan, HE Gendelman, Y Alnouti, 2013. Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrob. Agents Chemother. 57(7):3110-20.
  4. Upal Roy, J McMillan, Y Alnouti, N Gautum, N Smith, S Balkundi, P Dash, S Gorantla, A Martinez-Skinner, J Meza, G Kanmogne, S Swindells, S.M. Cohen, R.L Mosley, L Poluektova , H.E. Gendelman. 2012. Pharmacodynamic and antiretroviral activities of combination nanoformulatedantiretrovirals in HIV-1-infected human PBLreconstituted mice.J infectious Disease.206(10):1577-88. (Citation-7)
  5. P. Dash, H.E. Gendelman, Upal Roy, S. Balkundi, T.Gutti, J.Knibbe, E. Makarov, N. Smith, Y. Alnouti, R. L. Mosley, H.A. Gelbard, J. McMillan, S. Gorantla, and L.Poluektova. 2012 .Long-acting Nanoformulated Protease Inhibitors Show Potent Antiretroviral Responses in HIV-1 Infected Humanized Mice. AIDS.26(17):2135-44.(Citation – 6)
  6. G.D. Kanmogne, S. Singh, Upal Roy, X. Liu, J McMillan,SGorantla, S Balkundi, N Smith, Y Alnouti, N Gautam,Y Zhou, L Poluektova, A Kabanov, T Bronich and H E.Gendelman.2012.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell targeted nanoformulated antiretroviral drugs to human brain endothelial cells. International Journal of Nanomedicine 7.1-16.(Citation – 6)
  7. S Balkundi, A.S. Nowacek, R.S. Veerubhotla, H Chen, A Martinez-Skinner, Upal Roy, RL Mosley, G Kanmogne, X Liu, A.V. Kabanov, T Bronich, J McMillan, H.E. Gendelman.2011. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. International Journal of Nanomedicine.6:3393-404.(Citation – 9)
  8. J Huang,N Gautam, SP Bathena, Upal Roy,J McMillan, HE Gendelman, Y Alnouti.2011. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.Journal of Chromatography B879(23):2332-8.(Citation – 5)
  9. TZ Nazari-Shafti,E Freisinger,UpalRoy,CTBulot, C Senst, CL Dupin, AE Chaffin, SK Srivastava, D Mondal, EU Alt, R Izadpanah. 2011.Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection.Retrovirology.12;8(1):3. (Article is considered as 'Highly accessed' relative to age)(Citation – 1)
  10. S Balkundi,ASNowacek, UpalRoy, A Martinez-Skinner, J McMillan, H. E. Gendelman.2010. Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visual Experiments (46):pii 2460.doi.10.3791/2460. (Citation – 9)
  11. AS Nowacek, S Balkundi, J McMillan , Upal  Roy , A Martinez-Skinner , RL Mosley , G Kanmogne, AV Kabanov, T Bronich, HE Gendelman. 2011. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Control Release.150(2):204-11.(Citation – 25)
  12. Upal Roy, G Chakravarty, K Honer Zu Bentrup , D Mondal. 2009. Montelukast is a potent and durableinhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.Biological & pharmaceutical bulletin 32(12):2002-9.(Citation – 9)
  13. Upal Roy, S A. Simpson, D Mondal, S Eloby-Childress, E L. Winsor, M A. Beilke. 2008. Up-regulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro. Journal of Medical Virology. 80(3):494-500.(Citation – 5).
  14. M. A. Eilers, Upal Roy and D. Mondal. 2008.MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Experimental Biology and Medicine. (Maywood). 233(9).1149-1160. (Citation – 35)
  15. R Dixit, Upal Roy, Mi S. Patole, Y S. Shouche.2008. Molecular and Phylogenetic analysis of a novel family of fibrinogenrelated proteins from mosquito Aedesalbopictuscell line. Computational Biology and Chemistry 32. 382-386. (Citation – 5)
  16. R. Dixit., S. Dixit., UpalRoy, Y. Shouche and S Gakhar.2007. Partial genomic organization of ribosomal protein S7 gene from malaria vector Anopheles stephensi.Insect Science.14. 65-75. (Citation – 2)
  17. UpalRoy, D Nair.2007. Biodiversity of organotin resistant Pseudomonas from west coast ofIndia. Ecotoxicology. 16 (2), 253-261.(Citation – 3)
  18. T.P. Anand, A. W. Bhat., Y.S. Shouche., Upal Roy, J. Siddharth., S. P. Sharma. 2006. Antimicrobial activity of marine bacteria associated with marine sponges from the waters off the coast of south east India. Microbiological Research.161. 252-262. (Citation – 59)
  19. Upal Roy and S. Bhosle. 2006. Microbial transformation of tributyltin chloride by Pseudomonas aeruginosa strain USS25 NCIM-5224. Applied Organometallic Chemistry.20. 5-11.(Citation – 5)
  20. Upal Roy; S.K Dubey and S. Bhosle. 2004Tributyltin chloride degrading bacteria from marine environment of west coast of India. Current Science.85.702-705. (Citation – 12)
  21. Upal Roy, S. K. Dubey and S. Bhosle.2001.“Characterisation of Exopolymer Produced by Sphingomonas sp. Utilizing TBTC”. Proceedings of International Conference on Industrial Pollution and Control Technologies (ICIPACT-2001, JNTU, Hyderabad),639-642.
  22. S.K. Dubey andUpalRoy. 2003 Biodegradation of Tributyltins (organotins) by Marine   Bacteria. Applied Organometallic Chemistry.17. 3-8. (Citation – 67)